Congenital Diaphragmatic Hernia as a Potential Target for Transamniotic Stem Cell Therapy
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Nov 2019 · 1 min read
In brief
In brief
Preclinical study in a rat model demonstrates that transamniotic stem cell therapy (TRASCET) using amniotic fluid-derived mesenchymal stem cells modulates key growth factor expression in fetuses with congenital diaphragmatic hernia. Treated animals showed significant downregulation of FGF-10 and VEGF-A compared to controls, suggesting potential therapeutic benefit for this challenging prenatal condition.
Written by the GCMD Library team from the article.
Purpose
We sought to determine whether TRASCET could impact congenital diaphragmatic hernia (CDH).
Methods
Twelve pregnant dams received Nitrofen on gestational day 9.5 (E9; term = 22 days) to induce fetal CDH. Fetuses were divided into three groups: untreated (n = 31) and two groups receiving volume-matched intraamniotic injections of either saline (n = 37) or a suspension of 2 × 106 cells/mL of amniotic fluid-derived mesenchymal stem cells (afMSCs; n = 65) on E17. Animals were euthanized at term. Expression of fibroblast growth factor-10 (FGF-10), vascular endothelial growth factor-A (VEGF-A), and surfactant protein-C (SPC) was quantified by qRT-PCR. Statistical analysis was by the Mann–Whitney U test with Bonferroni adjusted criterion (p ≤ 0.01).
Results
Among survivors with CDH (n = 27/133), the TRASCET group showed significant downregulation of FGF-10 and VEGF-A gene expressions compared to the untreated (p